Telix adds another trial in its targeted radiation therapy development programme
The Phase I trial evaluates the combination Telix’s targeted radiation therapy with Merck’s peposertib, a DNA-PK Inhibitor.
The Phase I trial evaluates the combination Telix’s targeted radiation therapy with Merck’s peposertib, a DNA-PK Inhibitor.
What's Your Reaction?
